TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15891124
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg thalidomide daily for one week, followed by 50 mg/day for weeks 2 and 3, then dummy capsules in weeks 4 through 7.
Study: 15891124
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg thalidomide daily for one week, followed by gradual decrements every two weeks.
Study: 9585310
Drug: Clonidine 0.2-0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.2-0.3 mg per os
Study: 7712843
Drug: 120mg calcium
Normalized name: ubidecarenone 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg calcium daily
Study: 7712843
Drug: 240mg calcium
Normalized name: acetaminophen 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg calcium daily
Study: 7712843
Drug: 1g calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g calcium daily
Study: 7712843
Drug: 2g calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g calcium daily
Study: 2719293
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml saline solution and 0.5 ml clonidine (75 micrograms)
Study: 2719293
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml clonidine (150 micrograms)
Study: 2719293
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg of 0.5% hyperbaric tetracaine (HT) + 1 ml isotonic saline
Study: 29654915
Drug: MaZiRenWan (MZRW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MaZiRenWan (MZRW) 7.5 g, twice daily
Study: 29654915
Drug: Senna 15
Normalized name: Senna 15 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Senna 15 mg daily
Study: 16840386
Drug: Enalapril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (ACE inhibitor group)
Study: 16840386
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with ferrous sulfate, 525 mg
Study: 12867205
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment (mean daily dose 50 mg) in general practice
Study: 12867205
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment (mean daily dose 50 mg) in specialist clinics
Study: 9209246
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 500 mg azithromycin
Study: 9209246
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of two 250 mg azithromycin capsules
Study: 8221740
Drug: Gallopamil (GAL)
Normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallopamil (GAL) 50 mg tid
Study: 8221740
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AML) 10 mg/daily
Study: 30717693
Drug: Test &
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test & Treat TB intervention with immediate GeneXpert testing; participants received expedited TB treatment initiation, monthly SMS reminders, and non-cash incentives.
Study: 25483170
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation program (physical and occupational therapy for 60 min per day, five times a week, for four weeks)
Study: 23159962
Drug: 6 mL
Normalized name: ethanol 0.6 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mL bupivacaine 0.125% and 8 mg dexamethasone in a total volume of 8 mL (Group 2)
Study: 23159962
Drug: 8 mL
Normalized name: ethanol 0.8 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mL saline (Group 1)
Study: 12766625
Drug: d-Amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (0, 5, 10, and 15 mg)
Study: 3936140
Drug: Almitrine bismesylate
Normalized name: almitrine dimesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine bismesylate (200 mg/day for 9 days)
Study: 28585143
Drug: Single-allergen sublingual
Normalized name: American house dust mite allergenic extract / European house dust mite allergenic extract Sublingual Tablet [Odactra]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-allergen sublingual immunotherapy (SLIT) with a single HDM extract
Study: 28585143
Drug: Multi-allergen subcutaneous
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-allergen subcutaneous immunotherapy (SCIT) with multiple-allergen extracts (HDM and other allergens)
Study: 20087780
Drug: Robotic tumor-specific
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robotic tumor-specific rectal surgery (RTSRS)
Study: 19034219
Drug: ATG-Fresenius (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATG-Fresenius (9 mg/kg day 0; 3 mg/kg day 1-4)
Study: 19034219
Drug: Daclizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1 mg/kg day 0, 14, 28, 42, 56)
Study: 16598296
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Altastaph/kg
Study: 12947437
Drug: Filtered coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filtered coffee 600 ml/day for 4 weeks
Study: 9100202
Drug: Tetracycline hydrochloride
Normalized name: Tetracycline Hydrochloride
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline hydrochloride (50 mg/ml) root treatment for 5 minutes (TTC‐HCl group)
Study: 9100202
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid root treatment for 3 minutes (CA group)
Study: 7903034
Drug: Hydroxychloroquine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine and sulphasalazine combination treatment
Study: 3861844
Drug: Multivitamin and
Normalized name: Multivitamin and Minerals Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin and mineral supplements
Study: 31916533
Drug: Conventional pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological treatment plus respiratory physiotherapy (breathing and airway clearance techniques, exercise training, education for 3 weeks, 3 times per week)
Study: 31916533
Drug: Conventional pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional pharmacological treatment (control group)
Study: 24984177
Drug: Indapamide sustained-release
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide sustained-release 1.5 mg with the addition of perindopril 2-4 mg as required
Study: 16024091
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment with paroxetine
Study: 16024091
Drug: Antidepressant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant treatment with amitriptyline
Study: 11105495
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose prednisolone treatment
Study: 8800303
Drug: Griseofulvin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 1,000 mg once daily
Study: 6324587
Drug: Prophylactic intravenous
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intravenous administration of hyperimmune cytomegalovirus IgG at a dose of 200 mg/kg on days 25, 50, and 75 following transplant
Study: 6324587
Drug: Supporting treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supporting treatment control group
Study: 30920117
Drug: Four-drug metronomic
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug metronomic chemotherapy regimen (oral celecoxib b.i.d., weekly vinblastine, oral cyclophosphamide for three weeks alternating with oral methotrexate for three weeks, with a two-week rest)
Study: 30920117
Drug: Four-drug metronomic
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug metronomic chemotherapy regimen
Study: 31156913
Drug: Pharmacist complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist complex intervention (home visit at 1, 3, and 6 months) including medication review, medicines and lifestyle advice, PCI resolution, and supply of individualised patient information.
Study: 26803316
Drug: Rectal cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal cleansing enemas
Study: 19880673
Drug: Intensive exercise
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive exercise and risk reduction therapy including educational sessions, a low‐fat diet, and 2 hours of individually prescribed exercise daily.
Study: 17456521
Drug: Integrated smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated smoking cessation treatment within mental health care
Study: 15311146
Drug: No CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CPAP therapy (control group)
Study: 11136492
Drug: Failure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Failure to use perioperative antibiotics
Study: 9634157
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group treatment program (3 hours of group treatment, 3 days a week)
Study: 9634157
Drug: Weekly individual
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly individual outpatient counseling
Study: 9634157
Drug: Weekly individual
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly individual counseling plus one weekly group session
Study: 9634157
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who remained in treatment longer
Study: 9634157
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who remained in treatment
Study: 7608845
Drug: Tetracycline fiber
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline fiber therapy used adjunctively with scaling and root planing (S and RP)
Study: 3362944
Drug: 0.75 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 ml/kg ethanol
Study: 29617491
Drug: Elastic bandage
Normalized name: elastic bandage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic bandage and decongestant physical therapy
Study: 26147818
Drug: DentalVibe Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: DentalVibe Injection Comfort System (DV)
Study: 24105455
Drug: sirolimus (Rapamune
Approvals — FDA: no, EMA: no, PMDA: no
Description: sirolimus (Rapamune 2 mg/d) for 14 days
Study: 14981379
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg of misoprostol with saline solution (group I, 41 women)
Study: 14981379
Drug: 800 microg
Normalized name: Fentanyl 800 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 microg of misoprostol without saline solution (group II, 39 women)
Study: 9722720
Drug: Supragingival plaque
Normalized name: Plaquenil
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supragingival plaque control and oral hygiene instruction
Study: 30561562
Drug: Eravacycline 1
Normalized name: eravacycline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eravacycline 1 mg/kg every 12 hours for 4-14 days
Study: 30561562
Drug: Meropenem 1
Normalized name: meropenem 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 1 g every 8 hours for 4-14 days
Study: 27716665
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (2 g/day)
Study: 23382975
Drug: remifentanil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil (1 µg/ml)
Study: 23382975
Drug: remifentanil (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil (2 µg/ml)
Study: 21450224
Drug: Multifactorial fall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial fall prevention program (10 twice-weekly, 2-hour sessions with physical and psychological components and a booster session)
Study: 10831468
Drug: Adverse interpersonal
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse interpersonal events (e.g., death of a loved one)
Study: 2957348
Drug: Teicoplanin 400
Normalized name: Teicoplanin 400 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 400 mg intravenous bolus
Study: 24894344
Drug: Continuous erythropoietin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous erythropoietin receptor activator (CERA)
Study: 24240244
Drug: 13.5 mg
Normalized name: niacin 13.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 13.5 mg levonorgestrel intrauterine contraceptive system
Study: 24240244
Drug: 19.5 mg
Normalized name: camphor 19.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19.5 mg levonorgestrel intrauterine contraceptive system
Study: 16506273
Drug: Glibenclamide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glibenclamide (5 mg/d)
Study: 16506273
Drug: Nateglinide (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nateglinide (270 mg/d)
Study: 12672168
Drug: Alcohol received
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol received (0.5 g/kg)
Study: 12672168
Drug: Alcohol received
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol received (0.5 g/kg) with expectancy of alcohol (2-3 standard drinks)
Study: 12672168
Drug: No alcohol
Normalized name: BENZALKONIUM CHLORIDE 0.13 g in 100 mL TOPICAL SOLUTION [Zoono Alcohol Free Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: No alcohol received (0.0 g/kg) and no expectancy
Study: 11196347
Drug: 360 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg/day of anapsos
Study: 11196347
Drug: 720 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mg/day of anapsos
Study: 8008366
Drug: Tisacid suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisacid suspension (2.0 g)
Study: 8008366
Drug: Tisacid tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisacid tablet (2.0 g)
Study: 8008366
Drug: Tisacid suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisacid suspension (1.0 g)
Study: 8008366
Drug: Tisacid tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisacid tablet (1.0 g)
Study: 8008366
Drug: Tisacid suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisacid suspension (0.5 g)
Study: 8008366
Drug: Tisacid tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tisacid tablet (0.5 g)
Study: 8008366
Drug: Control (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (after administration of tablet or suspension)
Study: 3051475
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% (2 ml/cm incision) infiltrated into the fascia
Study: 18290864
Drug: Late hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late hypoglycaemia (nadir of 2.2 mmol/l after 3.5 h of sleep)
Study: 18290864
Drug: Early hypoglycaemia
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early hypoglycaemia (nadir of 2.2 mmol/l after 1 h of sleep)
Study: 16817277
Drug: Xuezhikang Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xuezhikang Capsules
Study: 11152307
Drug: Captia Select
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captia Select Toxo-G
Study: 9110115
Drug: Bosentan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (300 mg, intravenous)
Study: 9110115
Drug: Bosentan (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (0.5 g bid, orally for 14 days)
Study: 1530434
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of 5 micrograms of ISDN
Study: 1530434
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of 15 micrograms of ISDN
Study: 1530434
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of 60 micrograms of ISDN
Study: 1530434
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of 240 micrograms of ISDN
Study: 1530434
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of 1,000 micrograms of ISDN
Study: 1530434
Drug: Doses greater
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doses greater than 240 micrograms of ISDN
Study: 4093207
Drug: MONOCLAIR (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: MONOCLAIR (40 mg)
Study: 4093207
Drug: ISMO (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISMO (40 mg)
Study: 31410465
Drug: low SCFPns
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: low SCFPns (12 g SCFPns·steer‐1·d‐1)
Study: 31410465
Drug: medium SCFPns
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium SCFPns (15 g SCFPns·steer‐1·d‐1)
Study: 31410465
Drug: high SCFPns
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: high SCFPns (18 g SCFPns·steer‐1·d‐1)
Study: 31410465
Drug: eXPC (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: eXPC (7 g XPC·steer‐1·d‐1)
Study: 31410465
Drug: ANT (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT (330 mg monensin + 110 mg tylosin·steer‐1·d‐1)
Study: 24641778
Drug: evolutionary‐driven cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: evolutionary‐driven cognitive therapy (ED‐CT)
Study: 24641778
Drug: cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: cognitive therapy (CT)
Study: 22196576
Drug: Self-administered relaxation
Normalized name: endothelium-derived relaxing factor
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered relaxation techniques using a CD and booklet
Study: 18029326
Drug: Zofenopril 30
Normalized name: zofenopril 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zofenopril 30 mg + Hydrochlorothiazide 12.5 mg
Study: 2408179
Drug: Basal-bolus therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal-bolus therapy using pen-injectors
Study: 7332090
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg tramadol (Tramal)
Study: 7332090
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg buprenorphine (Temgesic)
Study: 19436939
Drug: Clodronate (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (800 mg daily)
Study: 9129851
Drug: Intravenous enalapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous enalapril
Study: 3063043
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics (gentamicin 160 mg + metronidazole 400 mg)
Study: 3063043
Drug: Systemic antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotics only (gentamicin 80 mg + metronidazole 500 mg intravenously)
Study: 17581533
Drug: Fentanyl (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70 kg)
Study: 17581533
Drug: Buprenorphine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine (0, 0.125, 0.5, 2, and 8 mg/70 kg)
Study: 17581533
Drug: Heroin (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heroin (0, 3.125, 6.25, 12.5, and 25 mg/70 kg)
Study: 17581533
Drug: Morphine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0, 6.25, 12.5, 25, and 50 mg/70 kg)
Study: 17581533
Drug: Oxycodone (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0, 6.25, 12.5, 25, and 50 mg/70 kg)
Study: 3767146
Drug: Intravenous propafenone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone, 2 mg/kg body weight
Study: 24681270
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (IIV) without OM-85 BV (n=35)
Study: 19834330
Drug: Sarpogrelate (oral)
Normalized name: Sarpogrelate
DrugBank: Sarpogrelate (DB12163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate (oral) for 12 weeks
Study: 16117986
Drug: Cefdinir oral
Normalized name: cefdinir Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir oral suspension 7 mg/kg q12h for 5 days
Study: 12218521
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg valdecoxib
Study: 12218521
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg valdecoxib
Study: 12971029
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg valdecoxib
Study: 2011701
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g sucralfate granulate given four times daily
Study: 22435877
Drug: Clinical improvement
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical improvement during the first 14 days of study therapy
Study: 12032720
Drug: naproxen ophthalmic
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: naproxen ophthalmic solution
Study: 7651474
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg of elemental zinc daily)
Study: 2528425
Drug: Yiqi Yangyin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yiqi Yangyin Huoxue prescription
Study: 1268617
Drug: Methyldopa (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (750 or 1000 mg)
Study: 1268617
Drug: Long-term methyldopa
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term methyldopa treatment
Study: 1268617
Drug: Methyldopa treatment
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa treatment for two to three weeks